-
1.发明公开
公开(公告)号：EP4461745A1
公开(公告)日：2024-11-13
申请号：EP22919084.8
申请日：2022-12-27
发明人： CHUNG, Eu Ddeum , RYU, Soomin , KIM, Donggeon , CHANG, Jihoon , LEE, Byoung Chul
摘要： The present invention relates to a fusion protein comprising an anti-C3b antibody or an anti-C5 antibody and an angiogenesis inhibitor, and a composition for treating eye diseases, particularly macular degeneration, by using the same. The protein may not only inhibit complement-related pathways, but can also efficiently regulate angiogenesis. Therefore, the fusion protein dimer can be effectively used to treat and prevent complement-related diseases, particularly eye diseases such as macular degeneration, and thus has high industrial applicability.
-
公开(公告)号：EP4198050A1
公开(公告)日：2023-06-21
申请号：EP21856206.4
申请日：2021-08-10
发明人： LEE, Dahea , RYU, Soomin , KIM, Donggeon , CHANG, Jihoon , LEE, Byoung Chul
摘要： The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to CD20. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-CD20 antibody is implemented in one antibody, IL-12 is specifically localized to a tumor site by targeting CD20, which is specifically expressed in a tumor at a high level, thereby efficiently treating cancer. Therefore, the bispecific antibody can be utilized as a pharmaceutical composition for anticancer treatment, and thus has a high potential for industrial application.
-
公开(公告)号：EP4198051A1
公开(公告)日：2023-06-21
申请号：EP21856207.2
申请日：2021-08-10
发明人： KIM, Donggeon , RYU, Soomin , LEE, Dahea , KIM, Dongsu , CHANG, Jihoon , LEE, Byoung Chul
摘要： The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-FAP antibody is implemented in one antibody, cancer may be efficiently treated by specifically targeting FAP expressed highly in a tumor, and specifically localizing IL-12 to the tumor site. Therefore, the bispecific antibody may be utilized as a pharmaceutical composition for anticancer treatment, and thus has high industrial application potential.
-
4.发明公开
公开(公告)号：EP4180453A1
公开(公告)日：2023-05-17
申请号：EP21838564.9
申请日：2021-07-07
发明人： CHUNG, Eu Ddeum , RYU, Soomin , KIM, Donggeon , CHANG, Jihoon , LEE, Byoung Chul
IPC分类号： C07K14/705 , C07K16/22 , A61K38/00 , A61P27/02
摘要： Provided is a fusion protein dimer containing an extracellular domain of CRIg or a fragment thereof, and a protein that specifically binds to VEGF. The protein may not only inhibit complement-related pathways, but also effectively modulate angiogenesis. Therefore, the fusion protein dimer may be effectively used for the treatment and prevention of complement-related diseases, specifically, eye diseases such as macular degeneration, and thus a high possibility of being industrially used.
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
